undamentalytics Newsletter
Sign in

Incyte insider trading

Every open-market purchase and sale by Incyte's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $82.8M 86 trades by 16 insiders 3 months later: median −0.3% (−0.8% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Incyte’s insiders pay?

From January 8, 2010 to March 10, 2022, 26 insiders reported 30 open-market purchases and 83 sales not made under a pre-set plan in Incyte. Twelve months after each purchase was reported, the shares were +9.2% against the S&P 500 on average (median +12.3%), over 30 purchases with a full year of prices; 60% beat the index. After sales, the shares moved +13.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 7, 2010 into $35,626 by November 2, 2026, +8.1% a year. It held shares 47% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $32,719 (+7.5% a year), and held throughout $94,920 (+14.8%).

$0$50.0k$100k 201020122014201620182020202220242026 $94.9k$35.6k$32.7k
Copying Incyte's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Incyte's insiders from July 7, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 47% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Friedman Paul A Chief Executive Officer 1 +44.1% (1) 100% 13 −11.3% (13) August 6, 2019
Whitfield Roy A Director 0 — — 10 −1.4% (10) May 25, 2012
Baker Felix Director 5 +9.7% (5) 40% 4 −9.4% (4) February 22, 2022
Chardonnet Laurent Other 0 — — 9 +22.8% (9) May 14, 2014
Bienaime Jean Jacques Director 6 −48.2% (6) 17% 2 −26.5% (2) November 12, 2020
Baker Julian Director 4 +10.2% (4) 75% 3 −6.3% (3) February 14, 2022
Hastings David C Chief Financial Officer 1 +44.1% (1) 100% 5 +64.8% (5) June 6, 2014
Swain Paula J EVP, Human Resources 0 — — 6 +42.8% (6) February 18, 2014
De Schutter Richard U Director 1 +178.5% (1) 100% 4 +53.1% (4) March 9, 2015
Levy Richard S EVP, Chief Drug Dev&Medical Of 0 — — 5 +61.8% (5) February 18, 2014
667, L.P. Director 4 +31.3% (4) 100% 0 — March 10, 2022
Siegel Eric H. EVP, General Counsel 0 — — 4 +41.7% (4) February 18, 2014
Ariko Barry A Director 0 — — 3 −6.9% (3) March 13, 2015
Brooke Paul A Director 1 −11.4% (1) 0% 2 −43.8% (2) March 20, 2017
Dixon Wendy L Director 1 +25.3% (1) 100% 2 −33.2% (2) August 31, 2020
Metcalf Brian W Chief Drug Discovery Scientist 0 — — 3 +10.9% (3) April 13, 2011
Schreck Patricia A EVP, General Counsel 0 — — 3 +1.6% (3) May 11, 2011
Baker Brothers Life Sciences Capital (gp), LLC Director 2 +12.3% (2) 100% 0 — December 7, 2011
Hoppenot Herve Chairman / CEO 2 −0.6% (2) 50% 0 — February 23, 2021
14159 Capital (gp), LLC Director 0 — — 1 −4.7% (1) August 11, 2010
Baker Biotech Capital (gp), LLC Director 0 — — 1 −4.7% (1) August 11, 2010
Baker Bros. Advisors LP Director 1 −64.7% (1) 0% 0 — September 8, 2017
Baker Bros. Capital (gp), LLC Director 0 — — 1 −4.7% (1) August 11, 2010
Baker Brothers Life Sciences LP Director 1 +110.0% (1) 100% 0 — March 17, 2016
Daly James M EVP, Chief Commercial Officer 0 — — 1 +13.0% (1) February 18, 2014
Friedman Steven M. EVP, Biology & Preclinical Dev 0 — — 1 +28.3% (1) January 8, 2010

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Incyte

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Incyte in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged +14.6% against the index. After 7 selling crowds, +4.5%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
February 28, 20223 buying+17.6%+10.3%+22.1%
February 29, 20162 buying+5.8%−3.2%+56.3%
February 27, 20153 selling+27.6%+37.1%−8.2%
February 28, 20149 selling−26.8%−24.5%+22.0%
September 30, 20136 selling+22.6%+30.4%+9.0%
February 28, 20134 selling−7.6%+48.3%+163.7%
May 31, 20126 selling−13.4%−26.7%−28.1%
December 30, 20114 buying+17.9%+55.7%−4.8%
April 29, 20114 selling−0.9%−15.7%+17.9%
August 31, 20107 selling+2.9%−17.1%+6.7%
July 30, 20102 buying+19.5%−4.6%+14.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Incyte · Funds · Politicians